Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04615065
Other study ID # 201900635
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 1, 2020
Est. completion date September 1, 2030

Study information

Verified date May 2022
Source University Medical Center Groningen
Contact Hjalmar Bouma, MD, PhD
Phone +31 50 361 6161
Email acutelines@umcg.nl
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Research in acute care faces many challenges, including enrollment challenges, legal limitations in data sharing, limited funding, and lack of singular ownership of the domain of acute care. To overcome some of these challenges, the Center of Acute Care of the University Medical Center Groningen in the Netherlands, has established a de novo data-, image- and biobank named "Acutelines". Acutelines is initiated to improve recognition and treatment of acute diseases and obtain insight in the consequences of acute diseases, including factors predicting its outcome. Thereby, Acutelines contributes to development of personalized treatment and improves prediction of patient outcomes after an acute admission.


Description:

Acutelines is a prospective biobank including patients with a broad spectrum of acute conditions. Its aim is to facilitate interdisciplinary research on the etiology and development of acute diseases with the aid of systematically collected biomaterials and medical data over various timepoints, both during the course of the patient's disease and after recovery. Clinical data, imaging data and biomaterial (i.e. blood, urine, feces, hair) are collected for patients presenting to the Emergency Department (ED) with a broad range of acute disease presentations. A deferred consent procedure (by proxy), is in place to allow collecting data and biomaterials prior to obtaining written consent. The digital infrastructure in place and the software used ensures automated capturing of all bed-side monitoring data (i.e. electrophysiological waveforms, vital parameters), and the secure importation of data from other sources, such as the electronic health records of the hospital, ambulance and general practitioner, municipal registration, health insurance companies and pharmacy. Follow up data are collected for all included patients during the first 72-hours of their hospitalization and 3-months, 1-year, 2-years and 5 years after their ED visit. Data and materials to be collected includes: - Demographic and health data (i.e. [experiences] health, quality of life, functional status) - Medical history (i.e. co-morbidity, intoxications, medication use) - Admission reason to emergency department - Physical examination and vital parameters - Clinical diagnostic data (i.e. [point-of-care] ultrasound, X-ray, CT-scan, laboratory results) - Electrophysiological waveforms (i.e. electrocardiogram [ECG], plethysmography) - Biomaterials - Treatment (i.e. medication use, non-pharmacological treatment, treatment decisions, length-of-stay in hospital, admission to intensive care unit [ICU])


Recruitment information / eligibility

Status Recruiting
Enrollment 35000
Est. completion date September 1, 2030
Est. primary completion date September 1, 2030
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria, at least one of the following: - Triaged as one of highest two triage categories (red or orange) according to the Manchester triage system; - Triaged as the third highest triage category (yellow) and arrival by EMS of Helicopter Emergency Medical Service (HEMS; - Shock - Suspicion of sepsis (based on either physicians' suspicion, Sepsis-2 or Sepsis-3 criteria) - Acute kidney injury (AKI) - Anaphylactic reaction - Syncope - Intoxication - Thrombosis - Pulmonary embolism - Bleeding while using anti-coagulant drugs - Gastro-intestinal bleeding - Electrolyte disturbance Exclusion Criteria: - Referred for organ transplantation as recipient - Transfer from other hospital - Accidental contact patient material (i.e. internal work-related accident) While data- and imaging will be collected from all these patients, biomaterials will only be collected from patients fulfilling the first criterion (i.e. triaged as one of highest two triage categories [red or orange] according to the Manchester triage system) and from patients with shock or a suspicion of sepsis.

Study Design


Related Conditions & MeSH terms

  • Acute Disease
  • Acute Kidney Injury
  • Anaphylaxis
  • Communicable Diseases
  • Complication of Treatment
  • Dyspnea
  • Electrolyte Disturbance
  • Embolism
  • Emergencies
  • Frailty
  • Hemorrhage
  • Infections
  • Intoxication by Drug
  • Pneumonia
  • Polypharmacy
  • Pulmonary Embolism
  • Sepsis
  • Shock
  • Skin Infection
  • Syncope
  • Thrombosis
  • Urinary Tract Infections

Locations

Country Name City State
Netherlands University Medical Center Groningen Groningen

Sponsors (1)

Lead Sponsor Collaborator
Hjalmar Bouma

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mortality (time and cause) Mortality will be retrieved from the electronic health records (EHR) from the hospital and municipal registration. The cause of death will be retrieved from the EHR from the hospital, general practitioner and Dutch statistics' office (CBS). Until the death of death from any cause, up to 50 years
Primary Katz ADL-6 (functioning) Katz ADL-6 (0-6, fully dependent-independent) Up to 1 year
Primary World Health Organization (WHO) performance status (functioning) World Health Organization (WHO) performance status (0-4, normal performance-bedridden) Up to 1 year
Primary Karnofsky performance score (functioning) Karnofsky performance score (10-100, moribund-normal performance) Up to 1 year
Primary Utrecht Activity List (daily activities) Utrecht Activity List (UAL; hours/week spend on (a) paid work, (b) education, (c) household, (d) running errands, (e) unpaid work, (f) sport, (g) hobbies, (h) other use of leisure time ) Up to 1 year
Primary Short QUestionnaire to ASsess Health-enhancing physical activity (daily activities) Short QUestionnaire to ASsess Health-enhancing physical activity (SQUASH; minutes/week and intensity of activity spend (a) commuting, (b) at work, (c) household activities and (d) leisure time; increased score corresponds with increased physical activity) Up to 1 year
Primary Quality of Life and experienced symptoms EuroQol-5D (EQ5D; simple descriptive profile and a single index value for health status; higher values corresponding with better health) with visual analogue scale (VAS; 0-100, worse-best experienced health) Up to 1 year
Primary Experienced somatic symptoms Patient Health Questionnaire-15 (PHQ-15; 0-30, minimal-high somatic symptom severity) Up to 1 year
Primary Fatigue Piper Fatigue Scale-12 (PFS-12; 0-10, higher scores reflect more fatigue among four subscales (a) behavior, (b) affect, (c) sensory, (d) cognition) Up to 1 year
Primary Patient Health Questionnaire-2 (mental health) Patient Health Questionnaire-2 (PHQ-2; 0-6, higher score corresponds to reduced mental health) Up to 1 year
Primary Patient Health Questionnaire-9 (mental health) Patient Health Questionnaire-9 (PHQ-9; 0-4 no depressive symptoms, 5-9 mild depressive symptoms, 10-14 moderate depressive symptoms, 15-19 moderately severe depressive symptoms, 20-27 severe depressive symptoms) Up to 1 year
Primary Geriatric Depression scale-15 (mental health) Geriatric Depression scale-15 (GDS-15; 0-4 no depressive symptoms, 5-10 mild depressive symptoms, 11-15 depressive symptoms) Up to 1 year
Primary Patient satisfaction Patient Satisfaction Questionnaire Short-form (PSQ-18; measuring general satisfaction, technical quality, interpersonal manner, communication, financial aspects, time spent with doctor, and accessibility and convenience; scored per domain, with lower scores corresponding with higher satisfaction) Up to 1 year
Primary Decision making Outcome prioritization tool (OPT; 0-100% per domain of prioritization for (a) life extension, (b) preserving independence, (c) reducing pain and (d) reducing other symptoms) Up to 1 year
Primary Co-morbidity Co-morbidity will be retrieved from the electronic health records (EHR) from the hospital, general practitioner and pharmacy. Data will be registered according to the Charlson' co-morbidity index (CCI; 1-2 mild co-morbidity, 3-4 moderate co-morbidity, 5 severe co-morbidity) Up to 5 years
Primary Length-of-stay in hospital/intensive care unit (ICU) Length-of-stay in hospital and on intensive care unit (ICU) in days Until hospital discharge, an average of 2 weeks
Secondary Biomarkers Laboratory values (Hb [mmol/L], leukocytes [/mL), trombocytes [/ml], creatinine [mmol/L], urea [mmol/L], CRP [mg/L], LDL cholesterol [mmol/L], HDL cholesterol [mmol/L], total cholesterol [mmol/L], AST [U/L], ALT [U/L], gGT [U/L], AF [U/L], bilirubin [microl/L], NTproBNP [pg/mL], troponin [microg/L]) will be retrieved from the electronic health records (EHR) from the hospital, general practitioner and pharmacy. Up to 5 years
Secondary Medication use Medication use will be retrieved from the electronic health records (EHR) from the hospital, general practitioner and pharmacy. Up to 5 years
Secondary Treatment (non-pharmacological, including organ support) Treatment (non-pharmacological) will be retrieved from the electronic health records (EHR) from the hospital, general practitioner and (helicopter) emergency medical service. Data will include intravenous fluid resuscitation, vasopressors, mechanical ventilation/non-invasive ventilation, oxygen supply, acute dialysis and extra-corporeal membrane oxygenation (ECMO) Until hospital discharge, up to 3 months
Secondary Sequential organ failure assessment (SOFA) SOFA scores will be available for patients admitted because of an infection. Up to 72 hours after hospitalization
Secondary Vital parameters Heart rate (bpm), blood pressure (mmHg), oxygen saturation (SpO2, SaO2, PaO2), breathing frequency (per min), consciousness (Glasgow coma scale), pain score (VAS), nausea/vomiting (y/n), defecation (y/n), urination (y/n), body weight (kg), length (cm), fluid balance (ml/day). Until hospital discharge, up to 3 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3
Not yet recruiting NCT04516395 - Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae N/A

External Links